Founded in 2009, the company is an Innovation driven and High-tech biopharmaceutical enterprise, focusing on the R&D, production and marketing of human-use vaccine. The company was listed in the National Equities Exchange and Quotations in September, 2015. In order to enrich the pipeline of Class 1 New Drugs, it is always pursuing the best-in-class technologies.
The company registered capital is 189.02 million CNY. The factory covers an area of 5.4 acres, with 77,000 m2 (828,800 square feet) in the construction plan and 39,000 m2 already finished and put into use.
Adhering to the business philosophy of "strengthening process management, committing to continuous improvement and pursuing the highest quality", the company aims to being the “internationally well-known and domestically leading” vaccine supplier. Through years’ hard working, its first product, Tetanus vaccine, Absorbed was issued the registration license in November.
The management team consists of professional personnel who have years’ experience in bio-pharmaceutical business and those have backgrounds of security, finance, marketing and overseas working or study experience. They have an average 20 years’ working experience. The management team has both good responsibility assigning and good team work spirits. Thus, the efficient running and high speed development of its businesses can be ensured.
Diversified Research & Development
It has an advanced R&D Platform, which enables it conduct not only Independent R&D to expand the current pipeline products, with the intellectual property protection, but also conduct Joint R&D to globally capture the latest technology, to get the most competitive products. The R&D Platform is also the first provincial bio-pharmaceutical service institute in Sichuan.
The company has also established official cooperation Griffith University, Australia on GAS Vaccine Development Project” and two parties open a labtory
The GAS vaccine is a needle-free, inhaled vaccine. With the help of liposome technology, active pharmaceutical ingredients of the vaccine can be encapsulated in a microballoon. Once inhaled through nasal cavity, the vaccine can be released in the respiratory tract, then the immunocyte can be activated and the immunization can be acquired.
(Group A Streptococcus (GAS) is a common bacterium that brings human infections, also is the most pathogenic to human among Streptococcus bacteria group. The most common clinical symptoms of GAS infection are listed as: tonsillitis, pustular sore, lymphadenitis, even scarlet fever, rheumatic fever, etc. Till now, worldwidely, no effective vaccine against GAS is approved for marketing. Professor Michael Good of Griffith university, speaks high of the vaccine for its safety and effectiveness. He thinks that in the future, the vaccine will make great contribution to human health. )
The intern needed will be based at the company's Overseas Project Development as a project assistant. Biology or Pharmacology are preferred.
Assist in maintaining thorough up-to-date knowledge on the status of current projects
Collecting data make report for team supervisor
Prepare knowledge-sharing presentations, if required, on emerging trends
Assist the company to keep in communication with foreign partners
Explore research/business opportunities with foreign research centres or potential commercial partners
Great opportunity of working in China and gaining international working experience
Monthly Cultural and social networking activities
Reference Letter from Host Company and Completion Certificate upon completion
Full-time job opportunities
To apply for the program please read more details on our Internship in China page and apply via there.